Please login to the form below

Not currently logged in
Email:
Password:

Mylan appoints two new board members

Melina Higgins is a former partner at Goldman Sachs and Rajiv Malik is president at Mylan

Generics firm Mylan has appointed to its board the company's president Rajiv Malik, as well as Melina Higgins, a former partner at investment bank Goldman Sachs.

Malik has been at the US-based company since 2007, when Mylan acquired Matrix Laboratories - a company Malik served at as CEO.

He has held several senior roles at Mylan, being appointed president in January 2012.

His current responsibilities include overseeing Mylan's research and development, business development, regulatory affairs, manufacturing operations and strategy, quality, supply chain, sourcing, packaging and medical affairs.

Malik has also helped Mylan expand into new commercial markets, including emerging countries like India.

Meanwhile, Higgins retired from Goldman Sachs in 2010 having spent more than 20 years at the firm.

She served in a number of senior positions, including head of the Americas and as co-chairperson of the investment advisory committee for the Goldman Sachs mezzanine partners funds, which managed over $30bn of assets.

Her financial background will aid Mylan as it continues its plans to expand globally, according to the company's chairman Robert Coury.

He said: “Our entire board and I have been extremely impressed with Melina's deep knowledge of, and experience in, the financial markets, understanding of optimal corporate structures and track record of unleashing shareholder value during her career in private equity.

“Melina also brings Mylan deep market insights and relationships across the financial community.”

Coury was similarly enthusiastic about Malik's appointment, saying he has made “extraordinary contributions throughout his tenure at Mylan”.

He continued: “[Malik] has helped generate meaningful value for our shareholders through his strong leadership and impressive operational and technical prowess, played an instrumental role in executing against Mylan's strategic growth drivers, and demonstrated unwavering commitment to Mylan and its mission.”

13th February 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics